CURRICULUM VITAE

Miriam Fernández Suárez, Psy. D.

Clinical Psychologist

Centro Especializado de Psiquiatría

1995 Road 2 Suite 1209-1210 Bayamón, Puerto Rico 00959-1201

Telephones: (787) 786-0575/780-3752 Fax: (787) 787-0412 Cellular: (787) 216-2242

Medical Licenses

Puerto Rico: 1894

Academic History

2000 Centro Caribeño de Estudios Post Graduados,

University Pedro Albizu San Juan, Puerto Rico

Doctor's Degree Clinical Psychology

1999-2000 Servicios Psicológicos y Consultivos, Inc (SPICI),

Humacao, Puerto Rico

Internship in Clinical Psychology

1994-1997 Centro Caribeño de Estudios Post Graduados,

Clínica de la Comunidad, San Juan, Puerto Rico

Clinical Psychology Practice

Publications

2000 The design of a Curriculum for a Doctor's Degree specialized

in Gerontology in Puerto Rico.

Experience

2009- Present Caribbean Education and Research Center.

Bayamón, Puerto Rico Independent Rater

Psychological Evaluations

2009- Present Centro Especializado en Psiquiatría, Bayamón, Puerto Rico

Private Practice

2008- Present Medical Psychiatric Center, Carolina Puerto Rico

Private Practice

2002-2008 Clínica Dr. Padró & Asociados, Guaynabo, Puerto Rico

Psychologist Coordinator

Coodinator for Primary Services in Partial Hospitalization, Ambulatory Program and Speaker for Psychological-

Educational directed to Factories.

2001-2002 Servicios Psicologicos Integrales, Inc., Humacao, Puerto

Rico

Psychologist

Services to Victims of Crimes, Domestic Violence and Sexual

Abuse

2000-2001 Department of Education, San Juan, Puerto Rico

Psychologist and Clinical Consultant

Psychological Services and consultation to High Schools for

the Multi-strategy for a Superior Education Program

1999-2000 Centro Caribeño de Estudios Post Graduados,

San Juan, Puerto Rico Clinical Supervisor

Supervision of Students in Module II-IV

Research

Novartis

Clinical Trial Protocol CAG0178C2302

An 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5 mg and 1mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD)

Sub-Investigator

2010-present

Novartis

Clinical Trial Protocol CAG0178C2399

A 52-Week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with

Major Depressive Disorder (MDD)

Sub-Investigator

Novartis

A 24 Week Open-Label Extension to Study CENA713DSU44: A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15cm2 Vs. Rivastigmine Patch 5 cm2 on ACTivities of Daily Living and CognitlON in Patients with Severe Dementia of the Alzheimer's Type (ACTION). Independent Rater

2009-Present	Novartis
--------------	----------

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi Center Study Comparing the Effects of Rivastigmine Patch 15cm2 vs. Rivastigmine Patch 5cm2 on Activities of Daily Living and Cognition in Patients with

Severe Dementia of the Alzheimer's Type.

Independent Rater

2003-2006 Instituto Latinoamericano, Inc. Guaynabo, Puerto Rico

Consultant

Investigation and Statistics on Educations Services for

Patients and Family Members

2001-2002 RECOPE, Humacao, Puerto Rico

Investigator

Investigation Based on Clinical Evaluations of the profile and

conduct on Mistreated Women.

2000-2001 Consultores Psicológicos y Psicoeducativos,

Hato Rey, Puerto Rico Investigation Consultant

Investigations Profiles of Adolescents Diagnosed with

Antisocial Personality Disorder

1999-2000 Department of Justice, Humacao, Puerto Rico

Consultant

Investigation and consultation for Crime Victims